The effects of metformin monotherapy and combination of metformin and glibenclamide therapy on the expression of , , and genes in peripheral blood mononuclear cells of type 2 diabetic patients.

Purpose: Although metformin is the first-line treatment of type 2 diabetes mellitus (T2DM), a few studies have evaluated the benefits of monotherapies (metformin) versus combination therapy (metformin and glibenclamide) for treatment of T2DM patients. The present study aimed to evaluate the effect of monotherapy with metformin compared to combination therapy with metformin and glibenclamide on the expression of , , and genes.

Methods: EightyT2DM patients and 40 healthy individuals participated in this case-control study.